Delcath Systems (NASDAQ:DCTH) Hits New 1-Year High – Time to Buy?

Delcath Systems, Inc. (NASDAQ:DCTH)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $15.80 and last traded at $15.81, with a volume of 298390 shares trading hands. The stock had previously closed at $15.21.

Analyst Ratings Changes

Several research firms have issued reports on DCTH. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research note on Tuesday, January 14th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Finally, Craig Hallum raised their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.25.

Delcath Systems Price Performance

The company’s 50-day moving average is $11.79 and its 200-day moving average is $10.08. The firm has a market capitalization of $515.68 million, a price-to-earnings ratio of -11.95 and a beta of 0.87.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Baader Bank Aktiengesellschaft purchased a new position in Delcath Systems in the fourth quarter valued at approximately $204,000. Principal Financial Group Inc. purchased a new position in Delcath Systems in the third quarter valued at approximately $808,000. Virtu Financial LLC purchased a new position in Delcath Systems in the third quarter valued at approximately $289,000. Barclays PLC purchased a new position in Delcath Systems in the third quarter valued at approximately $104,000. Finally, Geode Capital Management LLC raised its holdings in Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock valued at $2,275,000 after buying an additional 7,298 shares during the period. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.